Pharmacogenomic panel to predict chemotherapy- and immunotherapy-induced heart damage

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop a genetic and epigenetic test to forecast cardiotoxicity in cancer patients receiving chemotherapy or immunotherapy. It plans to enroll 1,000 breast cancer patients who are about to start anthracycline or HER2-targeted therapies and follow them for 12 months. Participants will undergo regular cardiac evaluations, including ECG, echocardiography with strain, and biomarkers such as Pro-BNP, BNP, and Troponin I. The goal is to enable early preventive strategies before cancer treatment begins to reduce the risk of left ventricular dysfunction and heart failure related to cancer therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with a confirmed diagnosis of breast cancer who are scheduled to initiate treatment with anthracyclines and/or HER2-targeted therapies (anti-HER2 therapies).

Exclusion Criteria:

* Patients with a left ventricular ejection fraction (LVEF) \< 50%;
* Patients who have undergone chemotherapy and/or radiotherapy within the previous year;
* Patients with chronic kidney disease and a glomerular filtration rate (GFR) \< 30 mL/min/1.73 m²;
* Patients with uncontrolled hypertension;
* Patients with complex congenital heart disease.

Where it's running

• Hospital BP - A Beneficência Portuguesa de São Paulo
  São Paulo, São Paulo, Brazil Recruiting
• Instituto do Câncer do Ceará
  Fortaleza, Ceará, Brazil Not yet recruiting
• Complexo Hospitar HUOC/PROCAPE
  Recife, Pernambuco, Brazil Not yet recruiting
• Universidade Federal de Santa Catarina
  Florianópolis, Santa Catarina, Brazil Not yet recruiting
• Hospital Beneficente UNIMAR
  Marília, São Paulo, Brazil Not yet recruiting
• FAMERP - Faculdade de Medicina de São José do Rio Preto
  São José do Rio Preto, São Paulo, Brazil Not yet recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

• Radiation-related heart damage in locally advanced NSCLC tested with PET-CT

  This study tests whether PET-CT imaging with 18F-Flurpiridaz can detect early radiation-related heart damage in adults with locally advanced non-small cell lung cancer receiving standard chemoradiation.

  Recruiting Phase 2 Indiana University · Indianapolis, Indiana · NCT07761910

• Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer

  This study tests whether heart changes seen on ultrasound and blood biomarkers can detect early heart problems in women receiving standard chemotherapy and anti-HER2 therapy for early breast cancer.

  Recruiting Gazi University · Ankara, Ankara · NCT07588425

• Serial contrast cardiac MRI and biomarker testing to detect anthracycline-related heart damage

  This study tries to see if repeated contrast cardiac MRI plus blood, urine, and stool biomarker checks can find early heart damage in people getting anthracycline chemotherapy.

  Recruiting Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) · Stuttgart · NCT07528586

• Early detection of heart and blood vessel damage from cancer treatments in children and young adults

  This project tests whether newer heart and vessel imaging and stiffness tests can find treatment-related damage earlier in children, adolescents, and young adult cancer patients.

  Recruiting at 5 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna and 4 other locations · NCT07382141

• Machine-learning prediction of heart damage from anthracycline or HER2 cancer therapies

  We will see if a machine-learning score can predict which adults starting anthracycline or HER2-targeted cancer therapies will develop heart damage within one year.

  Recruiting University Hospital, Caen · Caen · NCT07191730

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.